NSAIDS

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
Wednesday, November 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

Zoetis Welcomes Officials to Open New State-of-the-Art Facility in Lincoln

Retrieved on: 
Wednesday, August 9, 2023
Veterinary, Biotechnology, Pharmaceutical, Other Manufacturing, Pets, Health, Consumer, Manufacturing, Vaccine, Seizure, Osteoarthritis, Housing, Diarrhea, Hook effect, Atopic dermatitis, Stock, Multimedia, History, Tick, Pain, Vomiting, Animal, Dog, Cattle, Pet, Allergy, Kidney, Veterinary medicine, NSAIDS, Cat, Fine chemical, Zoetis, Animal Health, Lincoln

Source: Zoetis

Key Points: 
  • Source: Zoetis
    Today, Zoetis, the world leader in Animal Health, marked the official opening of its new monoclonal antibodies (mAbs) expansion with a ribbon cutting ceremony at its site in Lincoln, Neb.
  • Senator Pete Ricketts, Lincoln Mayor Gaylor Baird and key company leaders including Zoetis CEO Kristin Peck, and President of Global Manufacturing and Supply, Nick Ashton.
  • Located on 145 acres in the west side of Lincoln, Neb., the campus spans 1.4 million square feet, housing manufacturing, testing, and facility support buildings.
  • More recent incarnations of these animal health companies, including Zoetis, have continued to play an important economic role in the Lincoln community.

AppliedVR Awarded Contract with VHA Innovation Ecosystem, a division of the United States Department of Veterans Affairs

Retrieved on: 
Thursday, December 8, 2022
Therapy, VHA, NOV, VR, U.S. Department of Veterans Affairs, Office of Inspector General, Chronic pain, Patient, Injection, NSAIDS, Veterans Health Administration, ITX, FDA, Palliative care, Medicine, Virtual reality, Quality of life, News, Clinical trial, Multimedia, United States Department of Veterans Affairs, Anxiety, Ecosystem, Organization, Pharmaceutical industry, Publishing, Health insurance, Veteran

LOS ANGELES and WASHINGTON, Dec. 8, 2022 /PRNewswire/ -- AppliedVR, an immersive therapeutics (ITx) pioneer advancing a novel, virtual reality-based approach to medicine, today announced a contract with the U.S. Department of Veterans Affairs (VA) to provide its FDA-authorized RelieVRx (formerly EaseVRx) solution to select Veterans impacted by chronic lower back pain (CLBP). AppliedVR was awarded the contract with the VHA Innovation Ecosystem, a division of the VA that discovers, evaluates, and spreads mission-driven innovations that advance care delivery for Veterans.

Key Points: 
  • AppliedVR was awarded the contract with the VHA Innovation Ecosystem , a division of the VA that discovers, evaluates, and spreads mission-driven innovations that advance care delivery for Veterans.
  • AppliedVR Awarded Contract with VHA Innovation Ecosystem, a division of the United States Department of Veterans Affairs
    The Veterans Health Administration (VHA) provides care to more than 9 million Veterans, making it the largest integrated healthcare system in the U.S., and more than 50 percent of Veterans receiving care at VHA facilities across the country are affected by chronic pain.
  • AppliedVR and the VHA Innovation Ecosystem share a common vision to transform chronic pain care for our nation's Veterans by enabling more access to non pharmacological, noninvasive treatment options like virtual reality (VR).
  • Through this effort, healthcare providers at 18 VA facilities will have the ability to prescribe the RelieVRx program to Veterans for use in their homes.

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

Retrieved on: 
Thursday, September 29, 2022
Ljubljana University Medical Centre, Enzyme, Light, Safety, Trial of the century, SHINE, Biomarker, Blood, Glucose, NSAIDS, Diabetes, Ketone, Dexcom, Clinical trial, Exercise, CEO, Internet, UZA, Silicon, CGM, CMM, Gérard Delbeke, G6, Skin, Absorption, GLOW, Pharmaceutical industry, Medical device, Medical imaging, Indigo

BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.

Key Points: 
  • BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.
  • Indigo has recently submitted a paper on the data from its successfully concluded GLOW trial, the first-in-human clinical study of Indigos CMM sensor, to a peer-reviewed journal for publication.
  • Professor Christophe De Block, Principal Investigator of the SHINE trial at Antwerp University Hospital commented: Continuous monitoring of glucose levels is key in managing diabetes to prevent devastatingacute and long-term complications.
  • It is a privilege to lead the SHINE clinical trial to evaluate the safety and performance of this ground-breaking novel technology.

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

Retrieved on: 
Thursday, September 29, 2022
Ljubljana University Medical Centre, Enzyme, Light, Safety, Trial of the century, SHINE, Biomarker, Blood, Glucose, NSAIDS, Diabetes, Ketone, Dexcom, Clinical trial, Exercise, CEO, Internet, UZA, Silicon, CGM, CMM, Gérard Delbeke, G6, Skin, Absorption, GLOW, Pharmaceutical industry, Medical device, Medical imaging, Indigo

BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.

Key Points: 
  • BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.
  • Indigo has recently submitted a paper on the data from its successfully concluded GLOW trial, the first-in-human clinical study of Indigos CMM sensor, to a peer-reviewed journal for publication.
  • Professor Christophe De Block, Principal Investigator of the SHINE trial at Antwerp University Hospital commented: Continuous monitoring of glucose levels is key in managing diabetes to prevent devastatingacute and long-term complications.
  • It is a privilege to lead the SHINE clinical trial to evaluate the safety and performance of this ground-breaking novel technology.

Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Vertebral column, HIV disease progression rates, Pain, Spine, Weakness, Peng, Principal investigator, Hudson, Standard of care, Extracellular matrix, Degenerative disc disease, Disability, Ravindra, Radiofrequency ablation, DDD, Risk, NSAIDS, Moderate, Patient, Pharmaceutical industry, Dentistry, Injection

NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Spine BioPharma, Inc., a company committed to developing non-opiate, non-surgical therapies for the treatment of Chronic Low Back Pain (CLBP) and related disability caused by Degenerative Disc Disease (DDD), today announced the first patient treated in a Phase 3 clinical study of SB-01 For Injection (SB-01). The SB-01 Phase 3 study is known as the MODEL Study (Moderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine). SB-01 is the first intradiscal pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with DDD. 

Key Points: 
  • The SB-01 Phase 3 study is known as the MODEL Study (Moderate Severe Degenerative Disc Disease Evaluation of the Lumbar Spine).
  • SB-01 is the first intradiscal pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with DDD.
  • The patient was treated at Conquest Research in Winter Park, FL where Dr. Malisa Agard is the Principal Investigator.
  • The Phase 3 study of SB-01 is being conducted at 30 investigational sites across the US, enrolling up to 400 patients (Clinicaltrials.gov: NCT05516992 ).

Global Pain Management Drugs Market Report 2022-2027: Rise in Incidences of Chronic Diseases & Favorable Regulatory Scenario Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022
Health, Pharmaceutical, Risk, Others, Industry, Antidepressant, Ansoff Matrix, Pain scale, Growth, Investment, NSAIDS, Arthritis, Cancer pain, SWOT, Geography, CAGR, Neuropathic pain, Migraine, Market development, USD, Poultry, Fibromyalgia, Anesthetic, Anticonvulsant

The Global Pain Management Drugs Market is segmented based on Drug Class, Indication, Pain Type, and Geography.

Key Points: 
  • The Global Pain Management Drugs Market is segmented based on Drug Class, Indication, Pain Type, and Geography.
  • By Indication, the market is classified into Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Others.
  • The report presents a detailed Ansoff matrix analysis for the Global Pain Management Drugs Market.
  • The analyst analyses the Global Pain Management Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Gordon Robert Alton, PhD Joins BriOri BioTech as COO to Develop Patented Topical Formulation of Vioxx® Providing Those Suffering with Osteoarthritis a Long Lasting Non-Opioid Option for Pain Relief

Retrieved on: 
Monday, May 2, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, COO, NSAIDS, Seed (TV series), Pain, IND, Neuropathic pain, Autoimmunity, Stroke, Biomarker, Safety, Drug discovery, Patient, Doctor of Philosophy, Half-life, FDA, Knee, Osteoarthritis, R, Marketing, GI, Joint, Method, CRISPR, NSAID, IP, CEO, API, Regulation, HR, Pharmaceutical industry, The

I am pleased that Dr. Alton has joined our team at BriOri BioTech, says Bruce Register, PhD, Founder and CEO of BriOri BioTech .

Key Points: 
  • I am pleased that Dr. Alton has joined our team at BriOri BioTech, says Bruce Register, PhD, Founder and CEO of BriOri BioTech .
  • His proven experience to successfully drive pre-clinical R&D programs into early development will add to the success of the topical Vioxx program.
  • BriOri BioTechs state-of-the-art formulation capabilities will provide a platform of strong, nonaddictive pain relief to those who need it most.
  • BriOri BioTech is developing a platform topical chemistry that will allow for a pipeline of opiate-free topical pain medications.